Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | ACACA | Q13085 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7504049 | 0.89 | KDM4E (0.74) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL30702310 | 0.85 | KDM4E (1.00) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL5682766 | 0.83 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL29746285 | 0.83 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL6856561 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL27592710 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| Hydrochloric Acid SCHEMBL38654589 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL23956222 | 0.81 | NPC1 (0.67) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL31193719 | 0.81 | KDM4E (0.76) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL27512544 | 0.80 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6410547-B1 | (4-OXY-3-(ARYL)PHENYL)PYRIDINE FOR TREATMENT, PROPHYLAXIS OF INFLAMMATION, ESP. INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE AIRWAYS, E.G. FOR ASTHMA THERAPY; INHIBITORS OF PDE 4 ISOENZYME; DOWN REGULATE OR INHIBIT TNF-ALPHA RELEASE | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6288092-B1 | BIPHENYL PYRIDINES, BENZAMIDES AND PENYLCARBOXY COMPOUNDS USED AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE 4 ISOENZYME ACTIVITY AND DOWN REGULATORS OR INHIBIT TUMOR NECROSIS FACTOR RELEASE; ANTIHISTAMINES AND ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| US-6090817-A | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | NOVARTIS AG (CH) | 2000-07-18 | — | — | US | disclosed |
| EP-0885193-A1 | TRIARYL COMPOUNDS | Novartis AG (CH) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032853-A1 | TRIARYL COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | ALDH1A1 747/4885SMN1; SMN2 4126/4885KDM4E 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.